-
Something wrong with this record ?
Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition
A. Misiachna, J. Konecny, M. Kolcheva, M. Ladislav, L. Prchal, J. Netolicky, S. Kortus, P. Zahumenska, E. Langore, M. Novak, K. Hemelikova, Z. Hermanova, M. Hrochova, A. Pelikanova, J. Odvarkova, J. Pejchal, J. Kassa, J. Zdarova Karasova, J....
Language English Country France
Document type Journal Article
- MeSH
- Excitatory Amino Acid Antagonists pharmacology MeSH
- Dizocilpine Maleate * pharmacology MeSH
- Excitatory Postsynaptic Potentials drug effects MeSH
- Hippocampus drug effects metabolism MeSH
- Humans MeSH
- Memantine pharmacology MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Neurons drug effects metabolism MeSH
- Receptors, N-Methyl-D-Aspartate * antagonists & inhibitors metabolism MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
N-methyl-D-aspartate receptors (NMDARs) play a significant role in developing several central nervous system (CNS) disorders. Currently, memantine, used for treating Alzheimer's disease, and ketamine, known for its anesthetic and antidepressant properties, are two clinically used NMDAR open-channel blockers. However, despite extensive research into NMDAR modulators, many have shown either harmful side effects or inadequate effectiveness. For instance, dizocilpine (MK-801) is recognized for its powerful psychomimetic effects due to its high-affinity and nearly irreversible inhibition of the GluN1/GluN2 NMDAR subtypes. Unlike ketamine, memantine and MK-801 also act through a unique, low-affinity "membrane-to-channel inhibition" (MCI). We aimed to develop an open-channel blocker based on MK-801 with distinct inhibitory characteristics from memantine and MK-801. Our novel compound, K2060, demonstrated effective voltage-dependent inhibition in the micromolar range at key NMDAR subtypes, GluN1/GluN2A and GluN1/GluN2B, even in the presence of Mg2+. K2060 showed reversible inhibitory dynamics and a partially trapping open-channel blocking mechanism with a significantly stronger MCI than memantine. Using hippocampal slices, 30 μM K2060 inhibited excitatory postsynaptic currents in CA1 hippocampal neurons by ∼51 %, outperforming 30 μM memantine (∼21 % inhibition). K2060 exhibited No Observed Adverse Effect Level (NOAEL) of 15 mg/kg upon intraperitoneal administration in mice. Administering K2060 at a 10 mg/kg dosage resulted in brain concentrations of approximately 2 μM, with peak concentrations (Tmax) achieved within 15 minutes. Finally, applying K2060 with trimedoxime and atropine in mice exposed to tabun improved treatment outcomes. These results underscore K2060's potential as a therapeutic agent for CNS disorders linked to NMDAR dysfunction.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019082
- 003
- CZ-PrNML
- 005
- 20241024111627.0
- 007
- ta
- 008
- 241015e20240724fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2024.117201 $2 doi
- 035 __
- $a (PubMed)39053419
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Misiachna, Anna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 245 10
- $a Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition / $c A. Misiachna, J. Konecny, M. Kolcheva, M. Ladislav, L. Prchal, J. Netolicky, S. Kortus, P. Zahumenska, E. Langore, M. Novak, K. Hemelikova, Z. Hermanova, M. Hrochova, A. Pelikanova, J. Odvarkova, J. Pejchal, J. Kassa, J. Zdarova Karasova, J. Korabecny, O. Soukup, M. Horak
- 520 9_
- $a N-methyl-D-aspartate receptors (NMDARs) play a significant role in developing several central nervous system (CNS) disorders. Currently, memantine, used for treating Alzheimer's disease, and ketamine, known for its anesthetic and antidepressant properties, are two clinically used NMDAR open-channel blockers. However, despite extensive research into NMDAR modulators, many have shown either harmful side effects or inadequate effectiveness. For instance, dizocilpine (MK-801) is recognized for its powerful psychomimetic effects due to its high-affinity and nearly irreversible inhibition of the GluN1/GluN2 NMDAR subtypes. Unlike ketamine, memantine and MK-801 also act through a unique, low-affinity "membrane-to-channel inhibition" (MCI). We aimed to develop an open-channel blocker based on MK-801 with distinct inhibitory characteristics from memantine and MK-801. Our novel compound, K2060, demonstrated effective voltage-dependent inhibition in the micromolar range at key NMDAR subtypes, GluN1/GluN2A and GluN1/GluN2B, even in the presence of Mg2+. K2060 showed reversible inhibitory dynamics and a partially trapping open-channel blocking mechanism with a significantly stronger MCI than memantine. Using hippocampal slices, 30 μM K2060 inhibited excitatory postsynaptic currents in CA1 hippocampal neurons by ∼51 %, outperforming 30 μM memantine (∼21 % inhibition). K2060 exhibited No Observed Adverse Effect Level (NOAEL) of 15 mg/kg upon intraperitoneal administration in mice. Administering K2060 at a 10 mg/kg dosage resulted in brain concentrations of approximately 2 μM, with peak concentrations (Tmax) achieved within 15 minutes. Finally, applying K2060 with trimedoxime and atropine in mice exposed to tabun improved treatment outcomes. These results underscore K2060's potential as a therapeutic agent for CNS disorders linked to NMDAR dysfunction.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a dizocilpinmaleát $x farmakologie $7 D016291
- 650 12
- $a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a antagonisté excitačních aminokyselin $x farmakologie $7 D018691
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a memantin $x farmakologie $7 D008559
- 650 _2
- $a neurony $x účinky léků $x metabolismus $7 D009474
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a excitační postsynaptické potenciály $x účinky léků $7 D019706
- 650 _2
- $a hipokampus $x účinky léků $x metabolismus $7 D006624
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Konecny, Jan $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Kolcheva, Marharyta $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Ladislav, Marek $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Prchal, Lukas $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic
- 700 1_
- $a Netolicky, Jakub $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Kortus, Stepan $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Zahumenska, Petra $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Langore, Emily $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Novak, Martin $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic
- 700 1_
- $a Hemelikova, Katarina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Hermanova, Zuzana $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Hrochova, Michaela $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Pelikanova, Anezka $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic
- 700 1_
- $a Odvarkova, Jitka $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Pejchal, Jaroslav $u University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Kassa, Jiri $u University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Zdarova Karasova, Jana $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Korabecny, Jan $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic
- 700 1_
- $a Soukup, Ondrej $u University Hospital Hradec Kralove, Biomedical Research Center, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defense, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 50005, Czech Republic. Electronic address: ondrej.soukup@fnhk.cz
- 700 1_
- $a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, Prague 4 14200, Czech Republic. Electronic address: martin.horak@iem.cas.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 178 (20240724), s. 117201
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39053419 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111621 $b ABA008
- 999 __
- $a ok $b bmc $g 2201728 $s 1231055
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 178 $c - $d 117201 $e 20240724 $i 1950-6007 $m Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20241015